Neurology and pain
68 public biotech companies we cover are developing treatments for ALS, Alzheimer's, Parkinson's, multiple sclerosis, epilepsy, pain and other nervous system conditions. 45 upcoming catalysts are listed below, with dates as the companies gave them.
Companies
- AC Immune SA (ACIU)Thesis Intact
Neuroinflammation, Parkinson's disease, Alzheimer's disease, Amyotrophic lateral sclerosis
- Acumen Pharmaceuticals (ABOS)Thesis Challenged
Alzheimer's disease
- Alpha Cognition (ACOG)Thesis Challenged
Alzheimer's disease, Mild traumatic brain injury
- Alterity Therapeutics (ATHE)Thesis Challenged
Multiple System Atrophy
- Alumis (ALMS)Thesis Challenged
Multiple sclerosis, Parkinson's disease
- Amylyx Pharmaceuticals (AMLX)Thesis Intact
Amyotrophic lateral sclerosis
- Anavex Life Sciences (AVXL)Thesis Broken
Rett syndrome, Fragile X syndrome, Alzheimer's disease
- ANI Pharmaceuticals (ANIP)Thesis Challenged
Multiple sclerosis
- Annexon (ANNX)Thesis Intact
Huntington's disease, Amyotrophic lateral sclerosis
- Aquestive Therapeutics (AQST)Thesis Challenged
Epilepsy, Seizure clusters, Parkinson's disease, Lennox-gastaut syndrome, and 1 more
- Arcus Biosciences (RCUS)Thesis Intact
Multiple sclerosis
- Arrowhead Pharmaceuticals (ARWR)Thesis Intact
Alzheimer's disease, Parkinson's disease, Huntington's disease, Spinocerebellar ataxia type 2, and 3 more
- Autolus Therapeutics (AUTL)Thesis Intact
Multiple sclerosis, Progressive multiple sclerosis
- Bicycle Therapeutics (BCYC)Thesis Challenged
Central nervous system disease
- Biohaven (BHVN)Thesis Challenged
Epilepsy, Focal epilepsy, Acute migraine, Parkinson's disease, and 1 more
- BioRestorative Therapies (BRTX)Thesis Challenged
Cervical discogenic pain
- BridgeBio Pharma (BBIO)Thesis Intact
Canavan disease
- CervoMed (CRVO)Thesis Challenged
Ischemic stroke, Dementia with Lewy bodies, Amyotrophic lateral sclerosis, Nonfluent variant primary progressive aphasia
- ClearPoint Neuro (CLPT)Thesis Challenged
Intracranial hemorrhage
- Clene (CLNN)Thesis Challenged
Amyotrophic lateral sclerosis
- Contineum Therapeutics (CTNM)Thesis Challenged
Chronic pain
- Coya Therapeutics (COYA)Thesis Intact
Alzheimer's disease, Frontotemporal Dementia, Amyotrophic lateral sclerosis
- CRISPR Therapeutics (CRSP)Thesis Intact
Multiple sclerosis, Stiff person syndrome, Neuromyelitis optica spectrum disorder, Myelin oligodendrocyte glycoprotein antibody-associated disease
- Design Therapeutics (DSGN)Thesis Intact
Huntington's disease
- Eupraxia Pharmaceuticals (EPRX)Thesis Intact
Knee osteoarthritis pain
- Fennec Pharmaceuticals (FENC)Thesis Intact
Cisplatin-induced ototoxicity
- Gain Therapeutics (GANX)Thesis Challenged
Parkinson's disease
- Grace Therapeutics (GRCE)Thesis Challenged
Aneurysmal subarachnoid hemorrhage
- Harrow (HROW)Thesis Challenged
Pain
- Heron Therapeutics (HRTX)Thesis Challenged
Postoperative pain, Postoperative pain management
- INmune Bio (INMB)Thesis Challenged
Alzheimer's disease
- Ionis Pharmaceuticals (IONS)Thesis Intact
Angelman syndrome, Alexander disease
- Keros Therapeutics (KROS)Thesis Intact
Amyotrophic lateral sclerosis
- Kiora Pharmaceuticals (KPRX)Thesis Intact
Epilepsy, Exploratory CNS indications
- Kyverna Therapeutics (KYTX)Thesis Intact
Stiff person syndrome, Progressive multiple sclerosis
- Lexeo Therapeutics (LXEO)Thesis Intact
Alzheimer's disease
- Lineage Cell Therapeutics (LCTX)Thesis Intact
Hearing loss, Spinal cord injury, Auditory neuropathy
- Lipocine (LPCN)Thesis Broken
Essential Tremor
- MeiraGTx (MGTX)Thesis Intact
Neuropathic pain, Parkinson's disease, Amyotrophic lateral sclerosis
- Mesoblast (MESO)Thesis Intact
Chronic low back pain
- Monte Rosa Therapeutics (GLUE)Thesis Intact
CNS inflammatory diseases
- Nektar Therapeutics (NKTR)Thesis Intact
Multiple sclerosis
- NervGen Pharma (NGEN)Thesis Challenged
Spinal cord injury, Chronic tetraplegia due to spinal cord injury
- Neumora Therapeutics (NMRA)Thesis Intact
Alzheimer's disease, Parkinson's disease, Amyotrophic lateral sclerosis, Agitation associated with dementia due to Alzheimer's disease
- Neurogene (NGNE)Thesis Intact
Rett syndrome
- NewAmsterdam Pharma Company (NAMS)Thesis Intact
Alzheimer's disease
- NewcelX (NCEL)Thesis Challenged
Multiple sclerosis, Amyotrophic lateral sclerosis, Neurodegenerative and metabolic disorders
- NextCure (NXTC)Thesis Broken
Alzheimer's disease
- NRx Pharmaceuticals (NRXP)Thesis Challenged
Anesthesia and pain (ANDA), Amyotrophic lateral sclerosis
- Ovid Therapeutics (OVID)Thesis Intact
Infantile spasms, Lewy body dementia, Focal onset seizures, Photosensitive epilepsy, and 5 more
- Palatin Technologies (PTN)Thesis Challenged
Prader-willi syndrome
- Passage Bio (PASG)Thesis Broken
Huntington's disease, Frontotemporal dementia
- Praxis Precision Medicines (PRAX)Thesis Intact
Epilepsy, Essential tremor, Focal onset seizures, Generalized epilepsy, and 7 more
- Precision BioSciences (DTIL)Thesis Intact
Multiple sclerosis, Progressive Multiple Sclerosis
- ProMIS Neurosciences (PMN)Thesis Intact
Parkinson's disease, Alzheimer's disease, Multiple system atrophy, Mild Alzheimer's disease, and 3 more
- ProQR Therapeutics (PRQR)Thesis Intact
Rett syndrome
- Quoin Pharmaceuticals (QNRX)Thesis Intact
Tuberous sclerosis complex
- Sarepta Therapeutics (SRPT)Thesis Challenged
Huntington's disease
- Serina Therapeutics (SER)Thesis Challenged
Parkinson's disease
- Stoke Therapeutics (STOK)Thesis Intact
Dravet syndrome, Syngap1 haploinsufficiency, SYNGAP-1 genetic neurodevelopmental disease
- Taysha Gene Therapies (TSHA)Thesis Intact
Tauopathy, Rett syndrome, Fragile x syndrome
- TG Therapeutics (TGTX)Thesis Intact
Relapsing multiple sclerosis, Progressive multiple sclerosis, Relapsing forms of multiple sclerosis
- Tiziana Life Sciences (TLSA)Thesis Challenged
Alzheimer's Disease, Multiple System Atrophy, Traumatic spinal cord injury, Amyotrophic lateral sclerosis, and 2 more
- Tonix Pharmaceuticals (TNXP)Thesis Challenged
Migraine, Fibromyalgia, Neuropathic pain, Prader-Willi syndrome, and 1 more
- Ultragenyx Pharmaceutical (RARE)Thesis Challenged
Angelman syndrome
- uniQure (QURE)Thesis Challenged
Huntington's disease, Refractory mesial temporal lobe epilepsy
- Viking Therapeutics (VKTX)Thesis Intact
X-linked adrenoleukodystrophy
- Xenon Pharmaceuticals (XENE)Thesis Challenged
Pain, Epilepsy, Dravet syndrome, Focal onset seizures, and 1 more
Drug pages
RelutrigineUlixacaltamideObecabtagene autoleucel (obe-cel)RexaceractMivocabtagene autoleucel (miv-cel)
Upcoming catalysts
Firm dates · a specific day set by the company or regulator
Next 90 days
- Dec 27in 63 daysRelutrigine · FDA decision · SCN2A and SCN8A developmental and epileptic encephalopathy
Later
- Jan 29in 96 daysUlixacaltamide · FDA decision · Essential tremor
- Mar 29in 155 daysDiazepam buccal film · FDA decision · Seizure clusters · ages 6-11
Estimated timing · a month, quarter, half-year or year-end the company gave
Expected in November 2026
- November 2026Neflamapimod · Phase 2a interim results · Nonfluent variant primary progressive aphasia
Expected by end of November 2026
- late 2026Sabirnetug · Phase 2 topline results (ALTITUDE-AD) · Alzheimer's disease · early
Expected in Q4 2026
- Q4 2026Rexaceract · Regulatory submission · Parkinson's disease
- Q4 2026Miv-cel · Phase 1 results · Progressive multiple sclerosis
- Q4 2026Miv-cel · BLA submission · Stiff person syndrome
- Q4 2026NMRA-511 · Results · Alzheimer's disease · agitation
- Q4 2026NMRA-511 · Phase 2 start · Alzheimer's disease · agitation
- Q4 2026OV329 · Trial start · Tuberous sclerosis complex-associated seizures
- Q4 2026Vormatrigine · Trial start (POWER3) · Epilepsy · standalone agent
- Q4 2026Relutrigine · Enrollment complete (EMERALD) · Developmental and epileptic encephalopathy
- Q4 2026Relutrigine · Pivotal topline results (EMERALD) · Developmental and epileptic encephalopathy · broad DEE
- Q4 2026TSHA-102 · Regulatory submission · Rett syndrome
Expected in H2 2026
- H2 2026BHV-7000 · Phase 3 topline results (RISE3) · Focal epilepsy
- H2 2026LD IL-2 · Phase 2 results · Alzheimer's disease
- H2 2026Azer-Cel · Phase 1 interim results · Progressive Multiple Sclerosis
- H2 2026NEK7 (second-gen) · IND submission · CNS inflammatory diseases · IL-1/NLRP3 inflammasome-driven
- H2 2026NKTR-0165 · Preclinical results · Multiple sclerosis
- H2 2026BRIUMVI · BLA submission · Relapsing forms of multiple sclerosis · initiation dosing optimization
Expected by end of 2026
- By year-end 2026ACI-19764 · Phase 1b interim results · Neuroinflammation
- year-end 2026ATH434 · Phase 3 start · Multiple System Atrophy
- year-end 2026 or early 2027Ublituximab (subcutaneous) · Phase 3 topline results · Relapsing forms of multiple sclerosis
Expected in January 2027
- January 2027Libervant Full Approval for 12+ Age Group
Expected in Q1 2027
- Q1 2027Obe-cel · Phase 1 interim results (BOBCAT) · Progressive multiple sclerosis
- Q1 2027CNM-Au8 · Phase 3 start (RESTORE-ALS) · Amyotrophic lateral sclerosis
- Q1 2027Neflamapimod · Phase 2a topline results · Nonfluent variant primary progressive aphasia
- Q1 2027Rexaceract · Phase 2 start · Parkinson's disease
- Q1 2027ZYNRELEF · Results · Postoperative pain management
- Q1 2027PMN310 · Phase 1b topline results (PRECISE-AD) · Mild cognitive impairment due to Alzheimer's disease · mild Alzheimer's disease
- Q1 2027; Q3 2027; H2 2027Zorevunersen · NDA submission · Dravet syndrome
- Q1 2027Foralumab · Phase 2 topline results · Alzheimer's Disease · early
Expected in Q2 2027
- early Q2 2027COYA 302 · Phase 2/3 topline results (ALSTARS) · Amyotrophic lateral sclerosis
Expected in H1 2027
- H1 2027ACI-19764 · Phase 1b final results · Neuroinflammation
- 1H 2027A-005 · Phase 2 topline results · Multiple sclerosis
- H1 2027AX-2402 · Trial start · Rett syndrome · MECP2 R270X
- H1 2027AMT-260 · Phase 1/2a results · Refractory mesial temporal lobe epilepsy
- 1H 2027SER-252 · Phase 1b topline results (SER-252-1b) · Advanced Parkinson's disease
- 1H 2027TSHA-102 · BLA submission · Rett syndrome · developmental plateau
- 1H 2027TSHA-102 · Phase 3 interim results (REVEAL) · Rett syndrome · developmental plateau
Expected by end of June 2027
- Mid 2027EBD · IND submission · Alzheimer's disease
Expected in July 2027
- July 2027GNK-301 · Phase 1 start · Amyotrophic lateral sclerosis
Expected in Q3 2027
- Q3 2027Rexlemestrocel-L · BLA submission · Chronic low back pain · degenerative disc disease
- Q3 2027Zorevunersen · Phase 3 results (EMPEROR) · Dravet syndrome